Document is current
Any future updates will be listed below
-
Authors
Xie, Xiaowen https://orcid.org/0000-0002-9884-1865
Zhang, Olivia https://orcid.org/0000-0002-4299-1485
Yeo, Megan J. R. https://orcid.org/0000-0002-7906-9080
Lee, Ceejay https://orcid.org/0000-0002-4128-9328
Tao, Ran
Harry, Stefan A.
Payne, N. Connor https://orcid.org/0000-0001-9513-6194
Nam, Eunju
Paul, Leena https://orcid.org/0000-0003-4100-334X
Li, Yiran https://orcid.org/0000-0002-6339-5324
Kwok, Hui Si https://orcid.org/0000-0002-2858-8876
Jiang, Hanjie https://orcid.org/0000-0001-6090-4552
Mao, Haibin
Hadley, Jennifer L. https://orcid.org/0000-0003-1918-747X
Lin, Hong
Batts, Melissa https://orcid.org/0009-0007-3130-6570
Gosavi, Pallavi M. https://orcid.org/0000-0002-0486-5787
D’Angiolella, Vincenzo https://orcid.org/0000-0001-8365-9094
Cole, Philip A. https://orcid.org/0000-0001-6873-7824
Mazitschek, Ralph https://orcid.org/0000-0002-1105-689X
Northcott, Paul A. https://orcid.org/0000-0002-1220-5252
Zheng, Ning https://orcid.org/0000-0002-1039-1581
Liau, Brian B. https://orcid.org/0000-0002-2985-462X
- License Information
-
More Information
Article History
Received: 13 February 2024
Accepted: 17 December 2024
First Online: 12 February 2025
Competing interests
: B.B.L. is a co-founder, shareholder and member of the scientific advisory board of Light Horse Therapeutics. N.Z. is one of the scientific cofounders and a shareholder of SEED Therapeutics. N.Z. serves as a member of the scientific advisory board of Synthex, Molecular Glue Lab and Differentiated Therapeutics with financial interests. R.M. is a scientific advisory board member and equity holder of Regenacy Pharmaceuticals. R.M. and N.C.P. are inventors on patent applications related to the CoraFluor TR-FRET probes used in this work. P.A.C. is a co-founder of Acylin Therapeutics and a consultant for Abbvie regarding p300 acetyltransferase inhibitors. The remaining authors declare no competing interests.
